RedHill Biopharma (RDHL) director discloses RSUs and ADS holdings

Rhea-AI Filing Summary

RedHill Biopharma Ltd. director Mamluk Roni has filed an initial ownership report detailing existing equity awards and share holdings. The filing shows 10,350 unvested restricted share units, each tied to one American Depositary Share (ADS). Each ADS represents 10,000 ordinary shares of RedHill Biopharma Ltd.

The RSUs are subject to time-based vesting conditions and are settled in ordinary shares. The report also discloses 1,350 ADSs that are convertible at any time at the holder’s election and have no expiration date. This Form 3 does not reflect new buy or sell transactions, only current beneficial ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mamluk Roni

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 613,500,000 shares (Direct); Ordinary Shares — 103,500,000 shares (Direct)

Footnotes (1)

1. Represents 10,350 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. Represents 1,350 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mamluk Roni

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	103,500,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(2)	(2)	Ordinary Shares	613,500,000	(2)	D

Explanation of Responses:

1. Represents 10,350 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

2. Represents 1,350 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

	/s/ Roni Mamluk	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does RedHill Biopharma (RDHL) director Mamluk Roni report in this Form 3?

The Form 3 reports Mamluk Roni’s existing equity interests in RedHill Biopharma. It discloses unvested restricted share units linked to American Depositary Shares and additional ADSs held, establishing the director’s beneficial ownership as of the reporting date.

How many restricted share units does Mamluk Roni hold in RedHill Biopharma (RDHL)?

Mamluk Roni holds 10,350 unvested restricted share units. Each RSU relates to one American Depositary Share, which in turn represents 10,000 ordinary shares. These RSUs are subject to time-based vesting and will be settled in ordinary shares upon vesting.

What are the terms of the RedHill Biopharma (RDHL) restricted share units reported?

The restricted share units are subject to time-based vesting conditions and are settled in ordinary shares. Each of the 10,350 RSUs corresponds to one ADS, and each ADS represents 10,000 ordinary shares, linking the awards directly to the company’s ordinary equity.

How many American Depositary Shares does Mamluk Roni directly hold in RedHill Biopharma (RDHL)?

Mamluk Roni directly holds 1,350 American Depositary Shares. These ADSs are described as convertible at any time at the holder’s election and having no expiration date, providing ongoing exposure to RedHill Biopharma’s underlying ordinary shares.

Does this RedHill Biopharma (RDHL) Form 3 show any recent insider buying or selling?

The Form 3 does not show insider buying or selling activity. Instead, it serves as an initial statement of beneficial ownership, listing existing unvested restricted share units and American Depositary Shares held by director Mamluk Roni on the reporting date.

How are RedHill Biopharma (RDHL) ADSs related to its ordinary shares in this filing?

Each American Depositary Share mentioned in the filing represents 10,000 ordinary shares of RedHill Biopharma. Both the 10,350 RSUs and 1,350 ADSs are tied to this ADS-to-ordinary-share relationship, defining the scale of the director’s economic interest.